Cerebrolysin (porcine brain-derived proteolytic peptide fraction) / EVER Pharma - LARVOL DELTA

Cerebrolysin, hemorrhagic transformation, and anticoagulation timing after reperfusion therapy in stroke: post hoc secondary analysis of the CEREHETIS trial. (PubMed, Front Pharmacol) - "In IVT-treated MCA stroke patients with HTI 1-4, Cerebrolysin may reduce HT hazard and advance the risk-equilibrium point by approximately 1-2 days. These findings are preliminary and hypothesis-generating, suggesting that Cerebrolysin may allow earlier-but individualized-anticoagulation resumption in selected high-risk patients, pending prospective validation."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Ischemic stroke

Comparative Efficacy of Interventions for Supratentorial Stroke: A Bayesian NMA with Meta-Regression (ISC 2026) - "Pharmacologic options (e.g., tranexamic acid, atorvastatin, cerebrolysin) showed no significant benefit for mortality or function compared with standard care. For acute supratentorial ICH, surgical approaches—especially minimally invasive endoscopic evacuation—yield superior 6-month survival and functional outcomes compared with medical therapy alone. Conventional craniotomy confers a moderate survival advantage. Pharmacologic adjuncts did not improve hard outcomes in this network."

Clinical • Cardiovascular

Surgical excision of cerebral glioma and multimodal treatment including Cerebrolysin: a case report. (PubMed, J Med Life) - "Clinically, patients may present with headache, nausea, vomiting, seizures, or subtle cognitive and motor deficits, progressing in severe cases to deterioration of consciousness. Incorporating cerebroprotective interventions in perioperative management represents a promising approach to enhance recovery, functional independence, and quality of life in neurosurgical oncology patients."

Journal • Brain Cancer • Cardiovascular • CNS Disorders • Epilepsy • Glioma • Hypertension • Oncology • Pain • Solid Tumor

Use of nootropics in Alzheimer's disease: An analysis of regulatory positions and drug policies in the countries of the Commonwealth of Independent States. (PubMed, Int J Risk Saf Med) - "We compared the results of Russia with other countries regulatory and policy positions.ResultsE-Library searches identified 11 nootropicspiracetam, citicoline, idebenone, vinpocetine, choline alfoscerate, Cerebrolysin®, Kortexin®, ethylmethylhydroxypyridine succinate, glycine, nicergoline, nimodipine. Eight nootropic have registration for use in all CIS countries (excluding idebenone, nimodipine), four (piracetam, nimodipine, nicergoline, idebenone) - in UK, nimodipine - in the USA, and idebenone - in EU...None is included on the WHO Model EML and the National EML of Kyrgyzstan, Only CPG of the RF recommend using two nootropics as adjuvant therapy of Alzheimer's disease, Cerebrolysin® and choline alfoscerate. CPG of the European Union, the United Kingdom, and the USA do not mention nootropics as potential treatment options for Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

Cerebrolysin Ameliorates Age-Induced Dendritic Spine Degeneration and Memory Decline in C57BL6 Mice. (PubMed, Neurochem Res) - "This study provides the first integrated demonstration that CBL enhances dendritic spine maturation and dendritic structural remodeling while concurrently improving cognitive outcomes within the same cohort of aged animals. Collectively, our findings position CBL as a promising therapeutic candidate to counteract age-related synaptic loss and cognitive decline, advancing current understanding of neuroprotective interventions in aging."

Journal • Preclinical • SYP

Combined citicoline and Cerebrolysin for neuroprotection in traumatic brain injury: a retrospective cohort analysis. (PubMed, Front Neurol) - "Combined treatment with citicoline and Cerebrolysin may offer additional benefits for neurological recovery in patients with severe traumatic brain injury. Although statistical significance was not reached, the observed trend supports the need for further prospective, controlled studies to explore potential therapeutic advantages."

Journal • Retrospective data • CNS Disorders • Critical care • Inflammation • Vascular Neurology

Delta power surge and alpha power decline in traumatic brain injury recovery: A quantitative EEG analysis of the CAPTAIN-rTMS trial. (PubMed, J Clin Transl Sci) - "Both repetitive transcranial magnetic stimulation (rTMS) and Cerebrolysin (CRB) are promising therapies regulating neural plasticity...We found overall slowing of brain electrical activity during recovery after TBI, which was further influenced by rTMS and CRB treatment. Resting-state relative power spectral densities correlate with neuropsychological measurements."

Journal • CNS Disorders • Vascular Neurology

Retraction Note: Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. (PubMed, BMC Neurosci) - No abstract available

Journal

Cerebroprotection in acute ischemic stroke: Perspectives on Combining Cerebrolysin with Recanalization Therapy. (PubMed, J Stroke Cerebrovasc Dis) - "The CERECAP program has generated compelling data demonstrating Cerebrolysin's alignment with current AIS reperfusion therapy concepts, particularly its role in early intervention targeting multiple pathways. We review these studies and discuss the critical need to clearly define the patient population that benefit most from adjunctive Cerebrolysin therapy in AIS."

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke

Cerebrolysin ameliorates ketamine-mediated anxiety and cognitive impairments via modulation of mitochondrial function and CREB/PGC-1α pathway. (PubMed, Mol Brain) - "Furthermore, CBL therapy upregulated the hippocampal expression of the proteins CREB, p-CREB, and PGC-1α compared with the ketamine-treated animals. It is speculated that treatment with CBL can attenuate ketamine-induced cognitive deficits and anxiety-like behaviors through the upregulation of the CREB/PGC-1α pathway and the improvement of mitochondrial function."

Journal • CNS Disorders • Cognitive Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: Ain Shams University | Trial primary completion date: Mar 2025 ➔ May 2025 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • CNS Disorders • Hematological Disorders • Vascular Neurology

Comparative effects of Cerebrolysin and Erythropoietin in dendritic spines and memory in an animal model of aging (Neuroscience 2025) - "In these groups, a recovery in the proportion of mushroom spines and a decrease in stubby spines were observed, suggesting maintenance of functional synaptic properties. These findings support the therapeutic potential of CBL and EPO in the prevention and treatment of structural and functional alterations associated with brain aging."

Preclinical • CNS Disorders

Therapeutic strategies in vascular cognitive impairment: A systematic review and meta-analysis. (PubMed, Alzheimers Dement) - "Considerable methodological heterogeneity across VCI trials undermined the strength of evidence for both positive and negative findings, ultimately decreasing confidence in the possibility of treating VCI. Ginkgo biloba extracts have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low. Future trials should focus on a single VCI subtype, prioritize interventions with a strong mechanistic rationale, standardize diagnostic criteria, ensure adequate power for chosen outcomes, test against placebo, and implement FAIR data sharing to accelerate therapeutic discovery."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Vascular Neurology

Cerebrolysin treatment in a case of post-herpes simplex encephalitis with neuropsychiatric symptoms. (PubMed, J Med Life) - "The patient was treated with acyclovir and dexamethasone in the acute phase, followed by Cerebrolysin administration in the post-acute phase. This case highlights the potential therapeutic role of Cerebrolysin in managing post-encephalitic cognitive dysfunction, underscoring the need for further studies."

Journal • CNS Disorders • Cognitive Disorders • Epilepsy • Herpes Simplex • Infectious Disease • Psychiatry

Safety and feasibility of cerebrolysin in treatment of primary intracerebral hemorrhage (CLINCH)-a prospective, randomized, open-label, blinded endpoint pilot trial. (PubMed, Front Neurol) - "The restrictive eligibility criteria may limit generalizability but enhance the likelihood of detecting treatment effects. If positive, results would support a larger confirmatory trial and inform the sample size."

Journal • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

EFFICACY OF CEREBROLYSIN TREATMENT AS AN ADD-ON THERAPY TO MECHANICAL THROMBECTOMY IN PATIENTS WITH ACUTE ISCHEMIC STROKE: FINAL RESULTS OF A PROSPECTIVE, OPEN LABEL STUDY. (WSC 2025) - "Cerebrolysin improved functional outcomes at 90 days and 12 months, accelerated neurological recovery, and reduced complications post-MT in patients with small ischemic core, good collateral circulation and effective recanalization at baseline. These findings warrant further evaluation in randomized trials."

Clinical • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders

CEREBROPROTECTION IN ACUTE ISCHEMIC STROKE: PERSPECTIVES ON COMBINING CEREBROLYSIN WITH RECANALIZATION THERAPY (WSC 2025) - "These recent findings support Cerebrolysin as a promising adjunctive treatment in AIS. Its multimodal cerebroprotective profile, including blood–brain barrier stabilization, may reduce reperfusion-associated complications and enhance recovery. Further confirmatory trials are warranted to validate its integration into standard AIS management."

Cardiovascular • Hematological Disorders • Ischemic stroke

CEREBROLYSIN IN LATERAL MEDULLA INFARCTION FROM VERTEBRAL ARTERY DISSECTION: A PILOT RETROSPECTIVE ANALYSIS (WSC 2025) - "This pilot study found no significant recovery benefit from Cerebrolysin in VAD-induced LMI, possibly due to small sample size. However, it provides novel insights into a rare stroke subtype, highlighting the need for larger trials to evaluate Cerebrolysin's role in targeted stroke populations. These findings may guide future research in personalized stroke rehabilitation."

Retrospective data • Cardiovascular • Ischemic stroke

CEREBROLYSIN AND INTRAVENOUS THROMBOLYSIS IN ISCHEMIC STROKE: A PROSPECTIVE BRAIN IMAGING ANALYSIS FROM THE CEREHETIS TRIAL (WSC 2025) - "Cerebrolysin was associated with favorable brain imaging dynamics, supporting its potential cytoprotective effects in AIS."

Clinical • Cardiovascular • Ischemic stroke

EFFICACY OF CEREBROLYSIN COMBINED WITH EXTENDED REHABILITATION ON UPPER LIMB RECOVERY IN SEVERE SUBACUTE STROKE: AN ONGOING RANDOMIZED CLINICAL TRIAL (WSC 2025) - "Cerebrolysin led to greater improvement in post-stroke upper limb motor function compared to placebo, as measured by ARAT and FMA-UE, with significant effects observed after three weeks and sustained at 90 days. This effect may be attributed to Cerebrolysin's multimodal impact on long-term neuroregeneration mechanisms, enhanced by extended neurorehabilitation."

Clinical • Cardiovascular

CEREBROLYSIN AMELIORATES NEUROCOGNITIVE IMPAIRMENT AND REDUCES INFLAMMATION IN A MURINE MODEL OF VASCULAR DEMENTIA (WSC 2025) - "Cerebrolysin demonstrates therapeutic potential for VaD by improving neurocognitive function, promoting white matter integrity, and reducing neuroinflammation in a BCAS-induced VaD mouse model. These findings suggest that Cerebrolysin may be a promising therapeutic agent for VaD and warrant further investigation in clinical trials."

Preclinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • Vascular Neurology • GFAP • MBP

CEREBROLYSIN AS ADD-ON THERAPY IN PATIENTS WITH HIGH HUNT-HESS GRADE SUBARACHNOIDAL HEMORRHAGE (WSC 2025) - "According to preliminary results Ccerebrolysin as an add-on drug may improve the 90-day functional outcome in patients with aSAH and initial Hunt-Hess grade III and higher."

Clinical • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

CREGS-2 - A MULTINATIONAL, HIGH-QUALITY COMPARATIVE EFFECTIVENESS TRIAL OF CEREBROLYSIN IN MODERATE ACUTE ISCHEMIC STROKE (WSC 2025) - "Safety profiles were comparable between groups. Data integrity was high (90.9% valid mRS at day 90), with a dropout rate of 5.7%.ConclusionsThe HQCER design of CREGS-2 confirms that well-designed real-world studies can generate reliable evidence on Cerebrolysin's effectiveness and safety in moderate acute ischemic stroke patients."

HEOR • Cardiovascular • Diabetes • Ischemic stroke • Metabolic Disorders

CIRCULATING TIGHT JUNCTION PROTEINS IN ACUTE ISCHEMIC STROKE PATIENTS AFTER REPERFUSION THERAPY COMBINED WITH CEREBROLYSIN (WSC 2025) - No abstract available

Clinical • Cardiovascular • Ischemic stroke

Left atrial occlusion in intracerebral hemorrhage with atrial fibrillation, herpes zoster, and stroke, improving stroke outcomes in China, and Cerebrolysin as a treatment for acute stroke. (PubMed, Int J Stroke) - No abstract available

Journal • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Herpes Zoster • Varicella Zoster